🇺🇸 FDA
Patent

US 10525051

Compositions and methods for achieving sustained therapeutic drug concentrations in a subject

granted A61KA61K31/4745A61K47/60

Quick answer

US patent 10525051 (Compositions and methods for achieving sustained therapeutic drug concentrations in a subject) held by Nektar Therapeutics expires Mon Jan 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Nektar Therapeutics
Grant date
Tue Jan 07 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
13
CPC classes
A61K, A61K31/4745, A61K47/60, A61P, A61P15/00